Methods and compositions for treating conditions of the eye
AssigneeMassachusetts Eye and Ear Infirmary
InventorsVassiliki Poulaki, Joan Miller, Evangelos Gragoudas
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an ansamycin analog or heat shock protein 90 inhibitor, for example, 17-allylamino-17-demethoxygeldanamycin.
Claims40
A method of treating unwanted choroidal neovasculature in a mammal, the method comprising the steps of:
- (a) performing photodynamic therapy on the unwanted choroidal neovasculature;
- and
- (b) administering to the mammal an ansamycin analog in an amount sufficient to decrease or inhibit photodynamic therapy-induced upregulation of vascular endothelial growth factor.
A method of treating unwanted choroidal neovasculature in a mammal, the method comprising the steps of:
- (a) performing photodynamic therapy on the unwanted choroidal neovasculature;
- and
- (b) administering to the mammal a heat shock protein 90 inhibitor in an amount sufficient to decrease or inhibit photodynamic therapy-induced upregulation of vascular endothelial growth factor.
An improved photodynamic therapy-based method of treating unwanted choroidal neovasculature in a mammal, the improvement comprising:
- administering to the mammal an ansamycin analog in an amount sufficient to mitigate a side effect associated with the photodynamic therapy.
An improved photodynamic therapy-based method of treating unwanted choroidal neovasculature in a mammal, the improvement comprising:
- administering to the mammal a heat shock protein 90 inhibitor in an amount sufficient to mitigate a side effect associated with the photodynamic therapy.
A method of treating unwanted choroidal neovasculature in a mammal, the method comprising the steps of:
- (a) administering to the mammal a compound selected from the group consisting of an ansamycin analog and a heat shock protein 90 inhibitor in an amount sufficient to permit an effective amount to localize in the choroidal neovasculature;
- (b) administering to the mammal an amount of photosensitizer sufficient to permit an effective amount to localize in the choroidal neovasculature;
- and
- (c) irradiating the choroidal neovasculature with laser light such that the light is absorbed by the photosensitizer so as to occlude the choroidal neovasculature.
Dependencies are inferred from the claim text.